

Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

APPENDIX I

2nd HALF-YEARLY FINANCIAL REPORT FOR THE REPORTING I	PERIOD 2019					
PERIOD END DATE 31/12/2019						
I. IDENTIFICATION DETAILS						
Corporate name: LABORATORIOS FARMACEUTICOS ROVI, S.A.						
	Tax ld No.					
Registered address: c/ Julián Camarillo, 35, 28037 Madrid	A-28041283					
II. INFORMATION SUPPLEMENTING THE PERIODIC INFORMATION PUBL	ISHED PREVIOUSLY					



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

1. INDIVIDUAL STATEMENT OF FINANCIAL POSITION (PREPARED USING NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

ASSETS		CURRENT PERIOD 31/12/2019	PREVIOUS PERIOD 31/12/2018
A) NON-CURRENT ASSETS	0040	138.744	99.549
1. Intangible assets:	0030	41.587	31.618
a) Goodwill	0031		
b) Other intangible assets	0032	41.587	31.618
2. Property, plant and equipment	0033	46.742	41.284
3. Investment property	0034		
4. Non-current investments in group and associated companies	0035	42.826	14.379
5. Non-current financial investments	0036	1.482	1.480
6. Deferred tax assets	0037	6.107	10.788
7. Other non-current assets	0038		
B) CURRENT ASSETS	0085	276.732	314.411
1. Non-current assets held for sale	0050		
2. Inventories	0055	67.749	37.195
3. Trade and other receivables	0060	157.608	193.373
a) Trade receivables for sales of goods and services	0061	142.350	184.738
b) Other receivables	0062	5.169	5.221
c) Current tax assets	0063	10.089	3.414
4. Current investments in group and associated companies	0064	55	36
5. Current financial investments	0070	-	17
6. Current accruals and prepayments	0071	3	3
7. Cash and cash equivalents	0072	51.317	83.787
TOTAL ASSETS (A+B)	0100	415.476	413.960



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

1. INDIVIDUAL FINANCIAL STATEMENTS (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

LIABILITIES AND EQUITY		CURRENT PERIOD 31/12/2019	PREVIOUS PERIOD 31/12/2018
A) EQUITY (A.1 + A.2 + A.3)	0195	269.329	248.421
A.1) EQUITY	0180	266.582	245.296
1. Capital:	0171	3.364	3.364
a) Authorized capital	0161	3.364	3.364
a) Less: uncalled capital	0162		
2. Share premium	0172	87.636	87.636
3. Reserves	0173	7.032	6.959
4. Less: treasury stock	0174	(10.341)	(8.812)
5. Retained earnings	0178	153.338	140.568
6. Other shareholder contributions	0179		
7. Profit or loss for period	0175	25.553	15.581
8. Less: interim dividend	0176		
9. Other equity instruments	0177		
A.2) ADJUSTMENTS FOR CHANGES IN VALUE	0188	(3)	(3)
Available-for-sale financial assets	0181	(3)	(3)
2. Hedging transactions	0182		
3. Other	0183		
A.3) GRANTS, DONATIONS AND LEGACIES RECEIVED	0194	2.750	3.128
B) NON-CURRENT LIABILITIES	0120	62.803	24.440
1. Non-current provisions	0115		
2. Non-current debt:	0116	54.329	16.131
a) Bank borrowings and debentures or other negotiable instruments	0131	45.000	7.113
b) Other financial liabilities	0132	9.329	9.018
3. Non-current debt with group and associated companies	0117	333	-
4. Deferred tax liabilities	0118	2.348	2.046
5. Other non-current liabilities	0135		
6. Non-current accruals	0119	5.793	6.263
C) CURRENT LIABILITIES	0130	83.344	141.099
Liabilities associated with non-current assets held for sale	0121		
2. Current provisions	0122	9.827	7.226
3. Current debt:	0123	9.138	17.496
a) Bank borrowings and debentures or other negotiable instruments	0133	7.116	15.603
b) Other financial liabilities	0134	2.022	1.893
4. Current debt with group and associated companies	0129	156	141
5. Trade and other payables:	0124	63.457	115.877
a) Trade payables	0125	56.674	110.174
b) Other payables	0126	6.783	5.703
c) Current tax liabilities	0127		
6. Other current liabilities	0136		
7. Current accruals	0128	766	359
TOTAL EQUITY AND LIABILITIES (A + B + C)	0200	415.476	413.960



LABORATORIOS FARMACEUTICOS ROVI, S.

IV. SELECTED FINANCIAL INFORMATION

2. INDIVIDUAL INCOME STATEMENT (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

		CURRENT	PREVIOUS	ACCUMULATED	ACCUMULATED
		PERIOD (2nd HALF)	PERIOD (2nd HALF)	PERIOD 31/12/2019	PREVIOUS PERIOD
(+) Net revenue	0205	201.812	144.125	379.221	291.202
(+/-) Change in inventories of finished	0206	1.705	(598)	13.653	(490)
products and work in progress	0206	1.705	(596)	13.033	(490)
(+) Work performed by the company on its	0207				
assets		(1.11.000)	(0.4.000)	(077.000)	(100.070)
(-) Supplies	0208	(141.608)	(94.030)	(277.098)	(190.379)
(+) Other operating income	0209	1.879	11	3.450	5.380
(-) Employee benefit expenses	0217	(16.407)	(15.703)	(34.490)	(32.744)
(-) Other operating expenses	0210	(34.644)	(34.684)	(66.661)	(67.113)
(-) Amortization and depreciation charges	0211	(4.692)	(3.931)	(9.331)	(7.753)
(+) Allocation of grants for non-financial assets and other	0212	402	460	685	864
	0213				
(+) Excess provisions (+/-) Impairment and gains/(losses) on	0213				
disposal of intangible assets and property,	0214	(342)	(31)	(342)	(39)
plant & equipment	0_11	(0.2)	(0.)	(0 .=)	(55)
(+/-) Other gains/(losses)	0215				
= OPERATING PROFIT/(LOSS)	0245	8.105	(4.381)	9.087	(1.072)
(+) Finance income	0250	32	37	17.066	12.845
(-) Finance expenses	0251	(321)	(254)	(624)	(684)
(+/-) Change in fair value of financial	0252	25	17	159	17
instruments					
(+/-) Exchange rate differences	0254	(47)	(56)	24	(56)
(+/-) Impairment and gains/(losses) on	0255	_	2	-	2
disposal of financial instruments	2050	(011)	(05.4)	10.005	10.101
= FINANCE PROFIT/(LOSS)	0256	(311)	(254)	16.625	12.124
= PROFIT/(LOSS) BEFORE TAX	0265	7.794	(4.635)	25.712	11.052
(+/-) Corporate income tax	0270	(1.637)	3.207	(159)	4.529
= PROFIT/(LOSS) FOR PERIOD ON CONTINUING OPERATIONS	0280	6.157	(1.428)	25.553	15.581
(+/-) Profit/(loss) for perid on discontinued					
operations, net of tax	0285				
= PROFIT/(LOSS) FOR PERIOD	0300	6.157	(1.428)	25.553	15.581

EARNINGS PER SHARE		Amount (X.XX euros)	Amount (X.XX euros)	Amount (X.XX euros)	Amount (X.XX euros)
Basic	0290	0,11	-0,04	0,46	0,30
Diluted	0295				



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

3. INDIVIDUAL STATEMENT OF CHANGES IN EQUITY

A. INDIVIDUAL STATEMENT OF RECOGNIZED INCOME AND EXPENSES (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

		CURRENT PERIOD 31/12/2019	PREVIOUS PERIOD 31/12/2018
A) PROFIT/(LOSS) FOR PERIOD (from Income Statement)	0305	25.553	15.581
B) INCOME OR EXPENSES CREDITED OR CHARGED DIRECTLY TO EQUITY:	0310	484	828
Measurement of financial instruments	0320	-	(1)
a) Available-for-sale financial assets	0021	-	(1)
b) Other income /(expenses)	0323		
2. Cash flow hedges	0330		
3. Grants, donations and legacies received	0340	646	1.105
4. Actuarial gains and losses and other adjustments	0344		
5. Other income or expenses credited or charged directly to equity	0343		
6. Tax effect	0345	(162)	(276)
C) TRANSFERS TO PROFIT AND LOSS:	0350	(862)	(1.190)
Measurement of financial instruments	0355		
a) Available-for-sale financial assets	0356		
b) Other income /(expenses)	0358		
2. Cash flow hedges	0360		
3. Grants, donations and legacies received	0366	(1.151)	(1.586)
4. Other income or expenses credited or charged directly to equity	0365		_
5. Tax effect	0370	289	396
TOTAL RECOGNIZED INCOME/(EXPENSES) (A+B+C)	0400	25.175	15.219



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

3. INDIVIDUAL STATEMENT OF CHANGES IN EQUITY

B. INDIVIDUAL STATEMENT OF CHANGES IN TOTAL EQUITY (1/2) (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

				Equity				Cuente	
CURRENT PERIOD		Share capital	Share premium and reserves	Treasury stock	Profit/ (loss) for the period	Other equity instruments	Adjust- ments for changes in value	Grants, donations and legacies received	Total equity
Closing balance at 01/01/2019	3010	3.364	235.163	(8.812)	15.581		(3)	3.128	248.421
Adjustments for changes in accounting policies	3011								
Adjustments for errors	3012								
Adjusted opening balance	3015	3.364	235.163	(8.812)	15.581		(3)	3.128	248.421
I. Total recognized income/(expenses)	3020				25.553			(378)	25.175
II. Transactions with shareholders or owners	3025		1.682	(1.529)	(4.420)				(4.267)
Capital increases/(reductions)	3026								
Conversion of financial liabilities to equity	3027								
3. Distribution of dividends	3028				(4.420)				(4.420)
4. Treasury stock transactions (net)	3029		1.682	(1.529)					153
5.Increases/(reductions) due to business combinations	3030								
6. Other transactions with shareholders or owners	3032								
III. Other equity transactions	3035		11.161		(11.161)				
Payments based on equity instruments	3036								
Transfers between equity items	3037		11.161		(11.161)				
3. Other changes	3038								
Closing balance at 31/12/2019	3040	3.364	248.006	(10.341)	25.553		(3)	2.750	269.329



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

3. INDIVIDUAL STATEMENT OF CHANGES IN EQUITY

B. INDIVIDUAL STATEMENT OF CHANGES IN TOTAL EQUITY (2/2) (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

Units: thousands of eu	1105	Fth.							
				Equity					
PREVIOUS PERIOD		Share capital	Share premium and reserves	Treasury stock	Profit/ (loss) for the period	Other equity instrume nts	Adjustment s for changes in value	Grants, donations and legacies received	Total equity
Closing balance at 01/01/2018 (comparative period)	3050	3.000	138.434	(8.407)	18.673		(2)	3.489	155.187
Adjustments for changes in accounting policies	3051								
Adjustments for errors	3052								
Adjusted opening balance (comparative period)	3055	3.000	138.434	(8.407)	18.673		(2)	3.489	155.187
I. Total recognized income/(expenses)	3060				15.581		(1)	(361)	15.219
II. Transactions with shareholders or owners	3065	364	84.008	(405)	(5.952)				78.015
1. Capital increases/(reductions)	3066	364	83.755						84.119
Conversion of financial liabilities to equity	3067								
3. Distribution of dividends	3068				(5.952)				(5.952)
4. Treasury stock transactions (net)	3069		253	(405)					(152)
5.Increases/ (reductions) due to business combinations	3070								
6. Other transactions with shareholders or owners	3072								
III. Other equity	3075		12.721		(12.721)				-
transactions 1. Payments based on equity instruments	3076								
Transfers between equity items	3077		12.721		(12.721)				
3. Other changes	3078								
Closing balance at 31/12/2018 (comparative period)	3080	3.364	235.163	(8.812)	15.581		(3)	3.128	248.421



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

4. INDIVIDUAL STATEMENT OF CASH FLOWS (PREPARED USING NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

		CURRENT PERIOD	PREVIOUS PERIOD
		31/12/2019	31/12/2018
A) CASH FLOWS FROM OPERATING ACTIVITIES (1+2+3+4)	0435	(30.035)	(10.114)
1.Profit/(loss) before tax	0405	25.712	11.052
2. Adjustments to profit/(loss)	0410	12.152	12.144
(+) Amortization and depreciation of intangible assets and property, plant and equipment	0411	9.331	7.753
(+/-) Other adjustments to profit/(loss) (net)	0412	2.821	4.391
3. Changes in working capital	0415	(60.206)	(36.096)
4. Other cash flows from operating activities:	0420	(7.693)	2.786
(-) Payment of interest	0421		
(+) Proceeds from dividends	0422		
(+) Proceeds from interest	0423		
(+/-) Proceeds from/(payments for) corporate income tax	0430	(8.087)	(3.141)
(+/-) Other proceeds from/(payments for) operating activities	0425	394	5.927
B) CASH FLOWS FROM INVESTING ACTIVITIES (1+2)	0460	(26.382)	(12.751)
1. Payments of investments:	0440	(26.539)	(15.342)
(-) Group companies, associates and business units	0441	(775)	-
(-) Property, plant and equipment, intangible assets and investment property	0442	(25.764)	(15.342)
(-) Other financial assets	0443		
(-) Non-current assets and liabilities classified as held for sale	0459		
(-) Other assets	0444		
2. Proceeds from disinvestments	0450	157	2.591
(+) Group companies, associates and business units	0451	-	50
(+) Property, plant and equipment, intangible assets and investment property	0452	75	2.199
(+) Other financial assets	0453		
(+) Non-current assets and liabilities classified as held for sale	0461		
(+) Other assets	0454	82	342
C) CASH FLOWS FROM FINANCING ACTIVITIES (1+2+3)	0490	23.947	71.126
Proceeds from and (payments for) equity instruments:	0470	153	87.848
(+) Issue	0471	-	88.000
(-) Amortization	0472		
(-) Acquisition	0473	(4.718)	(1.138)
(+) Disposal	0474	4.871	986
(+) Grants, donations and legacies received	0475		
2. Proceeds from and (payments for) financial liability instruments:	0480	28.214	(10.770)
(+) Issue	0481	47.033	7.043
(-) Repayment and amortization	0482	(18.819)	(17.813)
3. Payment of dividends and remuneration of other equity instruments	0485	(4.420)	(5.952)
D) EFFECT OF EXCHANGE RATE CHANGES	0492		
E) NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C+I	0495	(32.470)	48.261
F) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	0499	83.787	35.526
G) CASH AND CASH EQUIVALENTS AT END OF PERIOD (E+F)	0500	51.317	83.787

COMPONENTS OF CASH AND CASH EQUIVALENTS AT END OF PERIOD		CURRENT PERIOD 31/12/2019	PREVIOUS PERIOD 31/12/2018
(+) Cash in hand and at bank	0550	51.317	83.787
(+) Other financial assets	0552		
(-) Less: bank overdrafts repayable on demand	0553		
TOTAL CASH AND CASH EQUIVALENTS AT END OF PERIOD	0600	51.317	83.787



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 5. CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNDER IFRS ADOPTED) (1/2)

ASSETS		CURRENT PERIOD 31/12/2019	PREVIOUS PERIOD 31/12/2018
A) NON-CURRENT ASSETS	1040	193.326	148.696
1. Intangible assets:	1030	45.079	34.650
a) Goodwill	1031		
b) Other intangible assets	1032	45.079	34.650
2. Property, plant and equipment	1033	131.608	95.837
3. Investment property	1034		
4. Investments in group and associated companies accounted for using the equity me	1035	1.843	2.038
5. Non-current financial investments	1036	71	70
a) At fair value through profit or loss	1047	71	70
Of which, "Designated upon initial recognition"	1041		
b) At fair value through other comprehensive income	1042		
Of which, "Designated upon initial recognition"	1043		
c) At amortised cost	1044		
6. Non-current derivatives	1039		
a) Hedging instruments	1045		
b) Other	1046		
7. Deferred tax assets	1037	14.660	16.036
8. Other non-current assets	1038	65	65
B) CURRENT ASSETS	1085	317.885	254.004
Non-current assets held for sale	1050		
2. Inventories	1055	158.811	94.861
3. Trade and other receivables	1060	91.645	63.594
a) Trade receivables for sale of goods and services	1061	71.616	50.953
b) Other receivables	1062	9.925	9.227
c) Current tax assets	1063	10.104	3.414
4. Current financial assets	1070		
a) At fair value through profit or loss	1080		
Of which, "Designated upon initial recognition"	1081		
b) At fair value through other comprehensive income	1082		
Of which, "Designated upon initial recognition"	1083		
c) At amortised cost	1084		
5.Current derivatives	1076	-	17
a) Hedging instruments	1077	-	17
b) Other	1078		
6. Other current assets	1075	3	21
7. Cash and cash equivalents	1072	67.426	95.511
TOTAL ASSETS (A+B)	1100	511.211	402.700



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 5. CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNDER IFRS ADOPTED) (2/2)

Units: thousands of euros LIABILITIES AND EQUITY		CURRENT PERIOD	PREVIOUS PERIOD
A) FOURTY (A 4 A 0 A 0)	4405	31/12/2019	31/12/2018
A 1) EQUITY (A.1 + A.2 + A.3)	1195 1180	322.386 322.389	287.472 287.475
A.1) EQUITY	1171	3.364	3.364
1. Capital:	1161	3.364	3.364
a) Authorized capital	1162	3.304	3.304
b) Less: uncalled capital	1172	87.636	87.636
2. Share premium	1172	673	600
3. Reserves 4. Less treasury stock	1173	(10.341)	(8.812)
5. Retained earnings	1174	201.784	186.792
6. Other shareholder contributions	1178	201.764	100.732
7. Profit or loss for period	1175	39.273	17.895
8. Less: interim dividend	1176	39.273	17.095
9. Other equity instruments	1177		
A.2) ACCUMULATED OTHER COMPREHENSIVE INCOME		(3)	(3)
	1188 1186	(3)	(3)
Items not reclassified to profit and loss for the period Truits instruments hald at fair rate at the period.			
a) Equity instruments held at fair value through other comprehensive income	1185 1190		
b) Other 2. Items that may be reclassified to profit and loss for the period	1187	(3)	(3)
		(3)	(3)
a) Hedging transactions	1182		
b) Hedging differences	1184		
c) Share in other comprehensive income of joint ventures and other	1192		
d) Debt instruments held at fair value through other comprehensive income	1191	(2)	(2)
e) Other	1183	(3) 322.386	(3) 287.472
EQUITY ATTRIBUTED TO PARENT COMPANY (A.1 + A.2)	1189	322.300	201.412
A.3) NON-CONTROLLING INTERESTS	1193	82.116	27.716
B) NON-CURRENT ASSETS	1120	02.110	27.710
1. Grants	1117		
Non-current provisions Non-current financial liabilities:	1115	72.104	16.589
	1116	45.000	7.113
a) Bank borrowings and debentures or other negotiable securities b) Other financial liabilities	1131 1132	27.104	9.476
Deferred tax liabilities	1118	1.078	1.243
	1110	1.076	1.243
5. Non-current derivatives	1141		
a) Hedging instruments			
b) Other	1142	8.934	9.884
6. Other non-current liabilities	1135	106.709	87.512
C) CURRENT LIABILITIES	1130	100.709	07.312
Liabilities related to current assets held for sale Current provisions	1121		
Current provisions Current finanacial liabilities:	1122	12.572	17.635
	1123	7.116	15.603
a) Bank borrowings and debentures or other negotiable securities b) Other financial liabilities	1133 1134	5.456	2.032
		91.914	68.165
4. Trade and other payables:	1124	68.770	47.875
a) Trade payables b) Other payables	1125 1126	23.144	20.290
		23.144	20.290
c) Current tax liabilities 5. Current derivatives	1127	129	
a) Hedging instruments	1145 1146	129	-
TO A DECOURT HOUSE HO	1140	129	-
	11/7	1	
b) Other 5. Other current liabilities	1147 1136	2.094	1.712



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 6. CONSOLIDATED INCOME STATEMENT (UNDER IFRS ADOPTED)

Units: thousands of euros		CURRENT PERIOD (2nd HALF)	PREVIOUS PERIOD (2nd HALF)	ACCUMULA TED PERIOD 31/12/2019	ACCUMULAT ED PREVIOUS PERIOD 31/12/2018
(+) Net revenue	1205	203.777	156.894	381.313	303.203
(+/-) Change in inventories of finished products and work in progress	1206	534	331	21.414	9.050
(+) Work performed by the company on its assets	1207				
(-) Supplies	1208	(91.082)	(67.000)	(188.020)	(137.662)
(+) Other operating income	1209	-			
(-) Employee benefit expenses	1217	(35.759)	(33.914)	(72.512)	(70.180)
(-) Other operating expenses	1210	(43.314)	(40.983)	(81.946)	(76.496)
(-) Amortization and depreciation charges	1211	(9.501)	(6.186)	(18.216)	(12.044)
(+) Allocation of grants for non-financial assets and other	1212	777	833	1.151	1.587
(+/-) Impairment of intangible assets and property, plant & equipment	1214	(341)		(341)	
(+/-) Gains/(losses) on disposal of intangible assets and property, plant & equipment	1216				
(+/-) Other gains/(losses)	1215				
= OPERATING PROFIT/(LOSS)	1245	25.091	9.975	42.843	17.458
(+) Finance income	1250	48	9	51	16
a) Interest income calculated using the effective interest rate method	1262	48	9	51	16
b) Other	1263				
(-) Finance expenses	1251	(475)	(274)	(927)	(712)
(+/-) Change in fair value of financial instruments	1252	25	(23)	159	(23)
(+/-) Gains/(losses) due to the reclassification of financial assets held at amortised cost to financial assets held at fair value	1258				
(+/-) Gains/(losses) due to the reclasification of financial assets held at fair value through other comprehensive income to financial assets held at fair value	1259				
(+/-) Exchange rate differences	1254	(88)	(83)	(51)	(83)
(+/-) Impairment on disposal of financial instruments	1255				
(+/-) Gains/(losses) on disposal of financial instruments	1257				
a) Financial instruments at amortised cost	1260				
b) Rest of financial instruments	1261				
= FINANCE PROFIT/(LOSS)	1256	(490)	(371)	(768)	(802)
(+/-) Profit/(loss) of entities measured using the equity method	1253	(185)	49	(195)	24
= PROFIT/(LOSS) BEFORE TAX	1265	24.416	9.653	41.880	16.680
(+/-) Corporate income tax	1270	(1.304)	692	(2.607)	1.215
= PROFIT/(LOSS) FOR PERIOD FROM CONTINUING OPERATIONS	1280	23.112	10.345	39.273	17.895
(+/-)Profit/(loss) for period from discontinued operations, net of taxes	1285				
= CONSOLIDATED PROFIT/(LOSS) FOR PERIOD	1288	23.112	10.345	39.273	17.895
a) Profit/(loss) attributed to parent company	1300	23.112	10.345	39.273	17.895
b) Profit/(loss) attributed to non-controlling interests	1289	2012	10.040	00.270	17.000

EARNINGS PER SHARE		AMOUNT (X.XX euros)	AMOUNT (X.XX euros)	AMOUNT (X.XX euros)	AMOUNT (X.XX euros)
Basic	1290	0,42	0,20	0,71	0,35
Diluted	1295				



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

7. CONSOLIDATED STATEMENT OF RECOGNIZED INCOME AND EXPENSES (UNDER IFRS ADOPTED)

Units: thousands of euros		CURRENT		CURRENT	
		PERIOD	PERIOD	PERIOD	PERIOD
A) DROCKT//LOCO) FOR REPLOD (for my large and Obstance and	1005	(2nd HALF)	,	31/12/2019	31/12/2018
A) PROFIT/(LOSS) FOR PERIOD (from Income Statement)	1305	23.112	10.345	39.273	17.895
B) OTHER COMPREHENSIVE INCOME - ITEMS NOT RECLASSIFIED TO PROFIT AND LOSS FOR THE PERIOD	1310				
Remeasurement (reversal of remeasurement) of property, plant	1310				
and equipment and intangible assets	1311				
Actuarial gains and losses	1344				
3. Share in other recognized comprehensive income from	1077				
investments in joint ventures and associates	1342				
4. Equity instruments held at fair value through other	1346				
5. Other income and expenses not reclassified to profit and loss for					
the period	1343				
6. Tax effect	1345				
C) OTHER COMPREHENSIVE INCOME - ITEMS THAT MAY	1350				
SUBSEQUENTLY BE RECLASSFIED TO PROFIT AND LOSS FOR	1350				-1
1. Hedging transactions:	1360				
a) Gains/(losses) on remeasurement	1361				
b) Amounts transferred to profit and loss	1362				
c) Amounts transferred at initial value of hedged items	1363				
d) Other reclassifications	1364				
2. Conversion differences:	1365				
a) Gains/(losses) on remeasurement	1366				
b) Amounts transferred to profit and loss	1367				
c) Other reclassifications	1368				
3. Share in other recognized comprehensive income from	1370				
investments in joint ventures and associates	1370				
a) Gains/(losses) from measurement	1371				
b) Amounts transferred to profit and loss	1372				
c) Other reclassifications	1373				
4. Debt instruments held at fair value through other comprehensive income:	1381				
a) Gains/(losses) on remeasurement	1382				
b) Amounts transferred to profit and loss	1383				
c) Other reclassifications	1384				
5. Other comprehensive income and expenses that may	1075				
subsequently be reclassified to profit and loss for the period:	1375				-1
a) Gains/(losses) on remeasurement	1376				-1
b) Amounts transferred to profit and loss	1377				
c) Other reclassifications	1978				
6. Tax effect	1380				
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (A+B+C)	1400	23.112	10.345	39.273	17.894
a) Attributed to parent company	1398	23.112	10.345	39.273	17.894
b) Attributed to non-controlling interests	1399			20	



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

8. CONSOLIDATED STATEMENT OF CHANGES IN TOTAL EQUITY (UNDER IFRS ADOPTED) (1/2)

			Equity						
		Equity							
CURRENT PERIOD		Share capital	Share premium and reserves	Treasury stock	Profit/ (loss) for the per. attributed to parent company	Other equity instru- ments	Adjust- ments for changes in value	Non- controlling interests	Total equity
Closing balance at 01/01/2019	3110	3.364	275.028	(8.812)	17.895		(3)		287.472
Adjustments for changes in accounting policies	3111								
Adjustments for errors	3112								
Adjusted opening balance	3115	3.364	275.028	(8.812)	17.895		(3)		287.472
I. Total recognized income/(expenses)	3120				39.273				39.273
II. Transactions with shareholders or owners	3125		1.682	(1.529)	(4.420)				(4.267)
1. Capital increases/(reductions)	3126								
Conversion of financial liabilities to equity	3127								
3. Distribution of dividends	3128				(4.420)				(4.420)
Treasury stock transactions (net)	3129		1.682	(1.529)					153
5.Increases/(reductions) due to business combinations	3130								
6. Other transactions with shareholders or owners	3132								
III. Other equity transactions	3135		13.383		(13.475)				(92)
Payments based on equity instruments	3136								
Transfers between equity items	3137		13.475		(13.475)				
3. Other changes	3138		(92)						(92)
Closing balance at 31/12/2019	3140	3.364	290.093	(10.341)	39.273		(3)		322.386



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

8. CONSOLIDATED STATEMENT OF CHANGES IN TOTAL EQUITY (UNDER IFRS ADOPTED) (2/2)

			Equity attributed to parent company						
		Equity							
PREVIOUS PERIOD		Share capital	Share premium and reserves	Treasury stock	Profit/ (loss) for the per. attributed to parent company	Other equity instruments	Adjust- ments for changes in value	Non- controlling interests	Total equity
Closing balance at					, ,				
01/01/2018 (comparative	3150	3.000	179.855	(8.407)	17.241		(2)		191.687
period)				,					
Adjustments for changes in	0454								
accounting policies	3151								
Adjustments for errors	3152								
Adjusted opening balance	3155	3.000	179.855	(8.407)	17.241		(2)		191.687
I. Total recognized	3160				17.895		(1)		17.894
income/(expenses)	3100				17.095		(1)		17.094
II. Transactions with	3165	364	84.008	(405)	(5.952)				78.015
shareholders or owners	3103	304	04.000	(405)	(5.952)				76.013
1. Capital	3166	364	83.755						
increases/(reductions)	3100	004	00.700						
2. Conversion of financial	3167								
liabilities to equity									
3. Distribution of dividends	3168				(5.952)				(5.952)
4. Treasury stock transactions	3169		253	(405)					(152)
(net)	0.00			(.00)					(.0=)
5.Increases/(reductions) due	3170								
to business combinations									
6. Other transactions with	3172								
shareholders or owners									
III. Other equity transactions	3175		11.165		(11.289)				(124)
Payments based on equity									
instruments	3176								
Transfers between equity									
items	3177		11.289		(11.289)				
3. Other changes	3178		(124)						(124)
Closing balance at			(124)				ĺ		(1-1)
31/12/2018 (comparative	3180	3.364	275.028	(8.812)	17.895		(3)		287.472
period)				(/			(6)		
por 100/									



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 9.A. CONSOLIDATED STATEMENT OF CASH FLOWS (INDIRECT METHOD) (UNDER IFRS ADOPTED)

Units: thousands of euros		CURRENT PERIOD 31/12/2019	PREVIOUS PERIOD 31/12/2018
A) CASH FLOWS FROM OPERATING ACTIVITIES (1 + 2 + 3 + 4)	1435	(9.044)	8.531
1.Profit/(loss) before tax	1405	41.880	16.680
2. Adjustments to profit/(loss)	1410	17.769	12.699
(+) Amortization and depreciation of intangible assets and property, plant and equipment	1411	18.216	12.044
(+/-) Other adjustments to profit/(loss) (net)	1412	(447)	655
3. Changes in working capital	1415	(63.665)	(24.434)
4. Other cash flows from operating activities:	1420	(5.028)	3.586
(-) Payment of interest	1421		
(-) Payment of dividends and remuneration of other equity instruments	1430		
(+) Proceeds from dividends	1422		
(+) Proceeds from interest	1423	(93)	-
(+/-) Proceeds from/(payments of) corporate income tax	1424	(8.129)	(3.141)
(+/-) Other proceeds from/(payments for) operating activities	1425	3.194	6.727
B) CASH FLOWS FROM INVESTING ACTIVITIES (1+2+3)	1460	(40.472)	(26.242)
1. Payments of investments:	1440	(40.525)	(26.459)
(-) Group companies, associates and business units	1441		
(-) Property, plant and equipment, intangible assets and investment property	1442	(40.525)	(26.459)
(-) Other financial assets	1443		
(-) Non-current assets and liabilities classified as held for sale	1459		
(-) Other assets	1444		
2. Proceeds from disinvestments	1450	2	112
(+) Group companies, associates and business units	1451	-	50
(+) Property, plant and equipment, intangible assets and investment property	1452	2	62
(+) Other financial assets	1453		
(+) Non-current assets and liabilities classified as held for sale	1461		
(+) Other assets	1454		
3. Other cash flows from investing activities	1455	51	105
(+) Proceeds from dividends	1456		
(+) Proceeds from interest	1457	51	105
(+/-) Other proceeds from/(payments for) investing activities	1458		
C) CASH FLOWS FROM FINANCING ACTIVITIES (1+2+3+4)	1490	21.431	72.522
1. Proceeds from and (payments of) equity instruments:	1470	153	87.848
(+) Issue	1471	-	88.000
(-) Amortization	1472		
(-) Acquisition	1473	(4.718)	(1.138)
(+) Disposal	1774	4.871	986
2. Proceeds from/ (payments for) financial liability instruments:	1480	25.791	(9.187)
(+) Issue	1481	47.033	7.043
(-) Repayment and amortization	1482	(21.242)	(16.230)
3. Payment of dividends and remuneration of other equity instruments	1485	(4.420)	(5.952)
4. Other cash flows from financing activities	1486	(93)	(187)
(-) Payment of interest	1487	(93)	(187)
(+/-) Other proceeds from /(payments for) financing activities	1488		
D) EFFECT OF CHANGES IN EXCHANGE RATES	1492		
E) NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C+D)	1495	(28.085)	54.811
F) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	1499	95.511	40.700
G) CASH AND CASH EQUIVALENTS AT END OF PERIOD (E+F)	1500	67.426	95.511

COMPONENTS OF CASH AND CASH EQUIVALENTS AT END OF PERIOD	CURRENT PERIOD 31/12/2019	PREVIOUS PERIOD 31/12/2018	
(+) Cash in hand and at bank	1550	67.426	95.511
(+) Other financial assets	1552		
(-) Less: bank overdrafts repayable on demand	1553		
TOTAL CASH AND CASH EQUIVALENTS AT END OF PERIOD	1600	67.426	95.511



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 10. DIVIDENDS PAID

		CURRENT	T PERIOD	PREVIOU:	S PERIOD
		Euros per share (X.XX)	Amount (thousand euros)	Euros per share (X.XX)	Amount (thousand euros)
Ordinary shares	2158	0,08	4.474	0,12	6.035
Other shares (non-voting, redeemable, etc.)	2159				
Total dividends paid	2160	0,08	4.474	0,12	6.035
a) Dividends charged to profit and loss	2155	0,08	4.474	0,12	6.035
a) Dividends charged to reserves or share premium	2156				
c) Dividends in kind	2157				
d) Flexible payment	2154				



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

11. SEGMENT REPORTING

Units: thousands of euros

Table 1:

Tubic 1.						
		Dis	tribution of net reven	ue by geographical a	area	
GEOGRAPHICAL AREA		INDIV	IDUAL	CONSOLIDATED		
	CURRENT PERIOD	PREVIOUS PERIOD	CURRENT PERIOD	PREVIOUS PERIOD		
Domestic market	2210	284.475	236.614	232.266	203.765	
Exports:	2215	94.746	54.588	149.047	99.438	
a) European Union	2216	77.691	42.037	129.825	84.967	
Eurozone	2217	71.521	39.562	105.217	69.064	
Non Eurozone	2218	6.170	2.475	24.608	15.903	
c) Other countries	2219	17.055	12.551	19.222	14.471	
TOTAL	2220	379.221	291.202	381.313	303.203	

Table 2:

			CONSO	LIDATED	
			ue from external omers	Profit	or loss
SEGMENTS		CURRENT PERIOD	PREVIOUS PERIOD	CURRENT PERIOD	PREVIOUS PERIOD
Manufacturing	2221	197.512	142.688	30.221	17.196
Marketing	2222	392.727	287.763	28.153	13.218
Other	2223			(33)	(7)
	2224				
	2225				
	2226				
	2227				
	2228				
	2229				
(-)Adjustments between segments	2230	(208.926)	(127.248)	(19.068)	(12.512)
TOTAL	2235	381.313	303.203	39.273	17.895



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 12. AVERAGE NUMBER OF EMPLOYEES

			IDUAL	CONSOL	LIDATED
		CURRENT PERIOD	PREVIOUS PERIOD	CURRENT PERIOD	PREVIOUS PERIOD
AVERAGE NUMBER OF EMPLOYEES	2295	506	471	1.293	1.209
Men	2296	216	196	600	542
Women	2297	290	275	693	667

IV. SELECTED FINANCIAL INFORMATION 13. COMPENSATION RECEIVED BY DIRECTORS AND SENIOR MANAGEMENT

DIRECTORS:

Item of compensation:		CURRENT PERIOD	PREVIOUS PERIOD	
Remuneration for membership of Board or Board committees	2310	510	510	
Salaries	2311	787	770	
Variable cash remuneration	2312	383	1.313	
Share-based remuneration systems	2313			
Indemnities	2314			
Long-term savings systems	2315	24	24	
Other	2316			
TOTAL	2320	1.704	2.617	

	Amount (thousand euros)		
SENIOR MANAGEMENT:		CURRENT	PREVIOUS
		PERIOD	PERIOD
Total compensation received by senior management	2325	1.894	1.773



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 14. RELATED-PARTY TRANSACTIONS AND BALANCES (1/2)

		CURRENT PERIOD				
EXPENSES AND INCOME		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
1) Finance expenses	2340					
2) Rentals	2343		25		2.036	2.061
3) Services received	2344					
4) Purchases of goods (finished or in progress)	2345					
5) Other expenses	2348					
EXPENSES (1+2+3+4+5)	2350		25		2.036	2.061
6) Finance income	2351					
7) Dividends received	2354					
8) Services provided	2356					
9) Sale of goods (finished or in progress)	2357					
10) Other income	2359					
INCOME (6+7+8+9+10)	2360					

		CURRENT PERIOD				
OTHER TRANSACTIONS		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
Financing agreements: loans & capital contributions (lender)	2372					
Financing agreements: loans & capital contributions (borrower)	2375					
Guarantees and guarantee deposits furnished	2381					
Guarantees and guarantee deposits received	2382					
Commitments acquired	2382					
Dividends and other profits distributed	2386		·			
Other transactions	2385					

		CURRENT PERIOD				
BALANCES AT END OF PERIOD		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
1) Customers and trade debtors	2341					
Loans and credits granted	2342					
3) Other amounts receivable	2346					
TOTAL BALANCES RECEIVABLE (1+2+3)	2347					
Suppliers and trade creditors	2352					
5) Loans and credits received	2353					
6) Other payment obligations	2355					
OTHER BALANCES PAYABLE (4+5+6)	2358					



LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 14. RELATED-PARTY TRANSACTIONS AND BALANCES (2/2)

RELATED-PARTY TRANSACTIONS		PREVIOUS PERIOD				
EXPENSES AND INCOME		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
1) Finance expenses	6340					
2) Rentals	6343		24		2.026	2.050
3) Services received	6344				200	200
4) Purchases of goods (finished or in progress)	6345					
5) Other expenses	6348					
EXPENSES (1+2+3+4+5)	6350		24		2.226	2.250
6) Finance income	6351					
7) Dividends received	6354					
8) Services provided	6356					
9) Sale of goods (finished or in progress)	6357				62	62
10) Other income	6359					
INCOME (6+7+8+9+10)	6360				62	62

		PREVIOUS PERIOD				
OTHER TRANSACTIONS		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
Financing agreements: loans & capital contributions (lender)	2372					
Financing agreements: loans & capital contributions (borrower)	2375					
Guarantees and guarantee deposits furnished	2381					
Guarantees and guarantee deposits received	2382					
Commitments acquired	2382					
Dividends and other profits distributed	2386					
Other transactions	2385					

		PREVIOUS PERIOD				
BALANCES AT END OF PERIOD		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
Customers and trade debtors	2341					
2) Loans and credits granted	2342					
Other amounts receivable	2346					
TOTAL BALANCES RECEIVABLE (1+2+3)	2347					
Suppliers and trade creditors	2352					
5) Loans and credits received	2353					
Other payment obligations	2355					
OTHER BALANCES PAYABLE (4+5+6)	2358					